Form 4/A for RMD ResMed|
Accepted 2022-11-18 00:00:00 ET · period of report 2022-11-15 · accession 0001127602-22-026089 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DA | 2022-11-18 | 2022-11-15 | RMD | BLAISE LUCILE | Pres, Sleep, RC Business | F - Tax | $225.18 | -169 | 6,819 | -2% | -$38.1K |
| DA | 2022-11-18 | 2022-11-16 | RMD | BLAISE LUCILE | Pres, Sleep, RC Business | A - Grant | $224.58 | +2,410 | 2,410 | New | +$541.2K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | ResMed Common Stock | 2022-11-15 | F | D | 169 | $225.18 | 6,819 | D | — | — | (F2) Reflects corrected share beneficially owned. |
| 2 | Derivative | ResMed Common Stock Options | 2022-11-16 | A | A | 2,410 | $224.58 | 2,410 | D | $224.58 · 2023-11-11 to 2029-11-16 | 2,410 ResMed Common Stock | (F3) Represents date options first become exercisable. Options vest 1/3 annually each November 11, 2023, 2024 and 2025. |